Arunjyoti Bio Ventures Ltd

Arunjyoti Bio Ventures Ltd’s share price declined to a fresh 52-week low of Rs.5.02 on 08 Jun 2026, marking a significant milestone in the stock’s ongoing downward trajectory. This new low reflects persistent pressures on the company’s financial performance and market valuation within the Non Banking Financial Company (NBFC) sector.

Arunjyoti Bio Ventures Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 03 Nov 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 01 June 2026, providing investors with the latest insights into its performance and prospects.

Arunjyoti Bio Ventures Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 03 Nov 2025, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed here represent the stock's current position as of 21 May 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Arunjyoti Bio Ventures Ltd, a micro-cap player in the Non Banking Financial Company (NBFC) sector, has seen a marked deterioration in its valuation parameters, shifting from a previously expensive profile to a risky one. This change, coupled with weak returns relative to the broader market and deteriorating profitability metrics, underscores growing investor caution and a challenging outlook for the stock.

Arunjyoti Bio Ventures Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 03 Nov 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 10 May 2026, providing investors with the latest insights into its performance and valuation.

Arunjyoti Bio Ventures Ltd is rated 'Strong Sell' by MarketsMOJO, a rating that was last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 April 2026, providing investors with an up-to-date view of the company's performance and outlook.

Arunjyoti Bio Ventures Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 17 April 2026, providing investors with an up-to-date view of its performance and outlook.

Arunjyoti Bio Ventures Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 03 Nov 2025, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 06 April 2026, providing investors with the latest perspective on the company’s position.

Arunjyoti Bio Ventures Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 26 March 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Arunjyoti Bio Ventures Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 03 Nov 2025, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 15 March 2026, providing investors with the latest comprehensive view of the company’s position.

Arunjyoti Bio Ventures Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 March 2026, providing investors with the latest insights into its performance and outlook.

Arunjyoti Bio Ventures Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 03 Nov 2025, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 20 February 2026, providing investors with the latest comprehensive view of the company’s position.

Arunjyoti Bio Ventures Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 03 Nov 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 09 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Arunjyoti Bio Ventures Ltd, a player in the Non Banking Financial Company (NBFC) sector, has reported a flat financial performance for the quarter ended December 2025, signalling a stabilisation after a period of negative trends. Despite this, the company’s long-term returns remain highly volatile, with recent downgrades reflecting cautious investor sentiment amid sector challenges.

Arunjyoti Bio Ventures Limited, a micro-cap non-banking financial company with a market capitalisation of ₹133.00 crores, is navigating challenging waters as the company transitions from its historical co-packing operations to financial services. Trading at ₹7.30 per share, the stock has declined 49.66% over the past year, significantly underperforming the Sensex's 8.49% gain during the same period. With a "Very Expensive" valuation grade and deteriorating financial trends, the company faces mounting pressure to demonstrate sustainable profitability and operational clarity.

Arunjyoti Bio Ventures Ltd, a micro-cap player in the Non Banking Financial Company (NBFC) sector, has recently formed a Death Cross, a significant technical indicator where the 50-day moving average crosses below the 200-day moving average. This development signals a potential deterioration in the stock’s trend and raises concerns about sustained bearish momentum in the near to medium term.

Arunjyoti Bio Ventures Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 03 Nov 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 29 January 2026, providing investors with the latest insights into its performance and valuation.